Abstract
Depression is frequently comorbid with functional dyspepsia, a relationship recognized in Traditional Chinese Medicine (TCM) for centuries. This study investigates the ZhikeShaoyao (ZS) drug pair, a key component of the Chaihu-Shugan-San formula, and its active compound synephrine. Using a Chronic Unpredictable Mild Stress (CUMS) rat model, researchers evaluated the antidepressant and prokinetic (gut-motility) effects of ZS. Results indicate that ZS and synephrine significantly reduce depressive behaviors, increase monoamine neurotransmitters (5-HT and NA), and suppress pro-inflammatory cytokines in the hippocampus. Furthermore, the treatment enhanced gastrointestinal motility by increasing ghrelin levels. Liquid chromatography-mass spectrometry (LC-MS) confirmed that synephrine successfully crosses the blood-brain barrier, reaching the hippocampus. These findings suggest that ZS acts through polypharmacological pathways to treat the gut-brain axis simultaneously.
Introduction
Depression rarely exists in isolation; it is often accompanied by gastrointestinal distress, specifically functional dyspepsia. In TCM, this clinical pairing is described as "liver constraint and spleen deficiency." While modern pharmacology often seeks a "one drug, one target" solution, complex conditions like depression-dyspepsia comorbidity may benefit from polypharmacology—where a single intervention modulates multiple biological targets.
The ZhikeShaoyao (ZS) drug pair has been used for over 2,000 years to treat these symptoms. This research aims to validate the efficacy of ZS and its primary absorbed compound, synephrine, in alleviating both the psychological and physical manifestations of depression in animal models.
Methods
To evaluate the dual effects of ZS, the researchers utilized a multi-faceted experimental approach:
- Animal Model: Chronic Unpredictable Mild Stress (CUMS) was used to induce depressive-like states and gastrointestinal dysfunction in rats.
- Behavioral Assessment: The Forced Swimming Test (FST), Tail Suspension Test (TST), and Open Field Test (OFT) were employed to measure levels of behavioral despair and locomotor activity.
- Molecular Analysis: The team used ELISA and Quantitative real-time PCR (qPCR) to quantify pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) in the hippocampus. They also measured monoamine neurotransmitters (5-HT and Noradrenaline).
- Cellular Modeling: BV2 microglia cells were treated with Lipopolysaccharides (LPS) to create an in vitro inflammation model to test the anti-inflammatory properties of ZS and synephrine.
- Gastrointestinal Metrics: Levels of ghrelin and acyl ghrelin were measured in the gastric antrum and plasma to assess gastrointestinal motility.
- Bioavailability: LC-MS was used to track the absorption and distribution of synephrine in the gut and the hippocampus.
Results
Behavioral and Neurochemical Improvements
Both ZS and synephrine treatments led to a significant reduction in immobility time during FST and TST ($P < 0.05$), indicating a reduction in depressive-like behavior. This was supported by a marked increase in 5-hydroxytryptamine (serotonin) and a highly significant boost in noradrenaline ($P < 0.001$).
Anti-Inflammatory Action
In both the CUMS rat model and the BV2 cell model, ZS and synephrine effectively inhibited the expression of pro-inflammatory cytokines. This suggests that the antidepressant effect is partially mediated by dampening neuroinflammation in the hippocampus.
Prokinetic Effects on the Gut
The study found that ZS and synephrine significantly enhanced gastrointestinal motility. This was linked to increased levels of acyl ghrelin ($P < 0.01$) and ghrelin ($P < 0.05$) in the gastric antrum and plasma. These hormones are critical for stimulating gastric emptying and appetite.
Bioactive Identification
A critical finding of the LC-MS analysis was the presence of synephrine in the hippocampus of the rats. This confirms that the compound is not only absorbed by the gut but is also capable of crossing the blood-brain barrier to exert direct effects on the central nervous system.
Discussion
The research demonstrates that the ZS drug pair operates through a sophisticated polypharmacological mechanism. By simultaneously targeting neurotransmission, neuroinflammation, and the endocrine regulation of the gut, ZS addresses the holistic nature of depression-dyspepsia comorbidity.
Synephrine appears to be a primary bioactive driver of these effects. Its ability to reach the hippocampus validates its role as a central nervous system modulator. This study provides a scientific basis for the ancient use of ZS and opens new avenues for developing natural antidepressants that treat the "whole patient" rather than just isolated symptoms.
Conclusion
ZS and synephrine represent a promising therapeutic strategy for depression, particularly when complicated by gastrointestinal issues. By enhancing monoamine levels, inhibiting inflammation, and stimulating gut motility, this drug pair offers a multi-target approach that aligns with the complex reality of the gut-brain axis.
Summary updated